Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela M Minassian

Showing results (21-30 of 67) with videos related to

Pageof 7
Sort By:
The Lancet. Respiratory Medicine|November 20, 2021
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trialSeth Toback, Eva Galiza, Catherine Cosgrove, et al.
NPJ Vaccines|January 6, 2024
PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trialFrancisco J Martinez, Michael White, Micheline Guillotte-Blisnick, et al.
Frontiers in Immunology|April 23, 2020
Better Epitope Discovery, Precision Immune Engineering, and Accelerated Vaccine Design Using Immunoinformatics ToolsAnne S De Groot, Leonard Moise, Frances Terry, et al.
The Journal of Experimental Medicine|April 11, 2025
Plasmodium falciparum infection induces T cell tolerance that is associated with decreased disease severity upon re-infectionDiana Muñoz Sandoval, Florian A Bach, Alasdair Ivens, et al.
Human Vaccines & Immunotherapeutics|November 13, 2012
Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trialRosalind Rowland, Ansar A Pathan, Iman Satti, et al.
Cell Reports. Medicine|March 25, 2021
Protein/AS01<sub>B</sub> vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectorsCarolyn M Nielsen, Ane Ogbe, Isabela Pedroza-Pacheco, et al.
Elife|March 2, 2021
Mapping immune variation and <i>var</i> gene switching in naive hosts infected with <i>Plasmodium falciparum</i>Kathryn Milne, Alasdair Ivens, Adam J Reid, et al.
Nature Microbiology|May 29, 2019
Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibodyThomas A Rawlinson, Natalie M Barber, Franziska Mohring, et al.
Frontiers in Immunology|March 18, 2026
B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settingsCaroline K Bundi, Olivia Muñoz, Elizabeth Kibwana, et al.
Frontiers in Immunology|February 1, 2024
Analyses of human vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigensJordan R Barrett, Sarah E Silk, Catherine G Mkindi, et al.
Pageof 7

Showing results (21-30 of 67) with videos related to

Sort By:
Pageof 7
The Lancet. Respiratory Medicine|November 20, 2021
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trialSeth Toback, Eva Galiza, Catherine Cosgrove, et al.
NPJ Vaccines|January 6, 2024
PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trialFrancisco J Martinez, Michael White, Micheline Guillotte-Blisnick, et al.
Frontiers in Immunology|April 23, 2020
Better Epitope Discovery, Precision Immune Engineering, and Accelerated Vaccine Design Using Immunoinformatics ToolsAnne S De Groot, Leonard Moise, Frances Terry, et al.
The Journal of Experimental Medicine|April 11, 2025
Plasmodium falciparum infection induces T cell tolerance that is associated with decreased disease severity upon re-infectionDiana Muñoz Sandoval, Florian A Bach, Alasdair Ivens, et al.
Human Vaccines & Immunotherapeutics|November 13, 2012
Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trialRosalind Rowland, Ansar A Pathan, Iman Satti, et al.
Cell Reports. Medicine|March 25, 2021
Protein/AS01<sub>B</sub> vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectorsCarolyn M Nielsen, Ane Ogbe, Isabela Pedroza-Pacheco, et al.
Elife|March 2, 2021
Mapping immune variation and <i>var</i> gene switching in naive hosts infected with <i>Plasmodium falciparum</i>Kathryn Milne, Alasdair Ivens, Adam J Reid, et al.
Nature Microbiology|May 29, 2019
Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibodyThomas A Rawlinson, Natalie M Barber, Franziska Mohring, et al.
Frontiers in Immunology|March 18, 2026
B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settingsCaroline K Bundi, Olivia Muñoz, Elizabeth Kibwana, et al.
Frontiers in Immunology|February 1, 2024
Analyses of human vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigensJordan R Barrett, Sarah E Silk, Catherine G Mkindi, et al.
Pageof 7